- Q4 2023 EyePoint Pharmaceuticals Inc Earnings Call TranscriptMar 07, 2024€24.4 (+5.17%)Earnings
- EyePoint Pharmaceuticals Inc at JPMorgan Healthcare Conference TranscriptJan 10, 2024
- EyePoint Pharmaceuticals Inc Conference call to discuss topline results TranscriptDec 04, 2023
- EyePoint Pharmaceuticals Inc to Host Virtual Key Opinion Leader TranscriptNov 09, 2023
- Q3 2023 EyePoint Pharmaceuticals Inc Earnings Call TranscriptNov 01, 2023€5.6 (+0.90%)Earnings
- EyePoint Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 26, 2023
- EyePoint Pharmaceuticals Inc at HC Wainwright Ophthalmology Virtual Conference - Panel Discussion TranscriptAug 16, 2023
- EyePoint Pharmaceuticals Inc at HC Wainwright Ophthalmology Virtual Conference - On-demand TranscriptAug 16, 2023
- Q2 2023 EyePoint Pharmaceuticals Inc Earnings Call TranscriptAug 02, 2023€10.9 (-2.68%)Earnings
- EyePoint Pharmaceuticals Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Q1 2023 EyePoint Pharmaceuticals Inc Earnings Call TranscriptMay 03, 2023€5.8 (-3.33%)Earnings
- EyePoint Pharmaceuticals Inc at Guggenheim Healthy Altitudes Summit TranscriptMar 15, 2023
- Q4 2022 EyePoint Pharmaceuticals Inc Earnings Call TranscriptMar 02, 2023€2.9 (-7.05%)Earnings
- Q3 2022 EyePoint Pharmaceuticals Inc Earnings Call TranscriptNov 02, 2022€5.5 (+0.92%)Earnings
- Q2 2022 EyePoint Pharmaceuticals Inc Earnings Call TranscriptAug 03, 2022€9.05 (+4.02%)Earnings
- EyePoint Pharmaceuticals Inc Investor Day TranscriptJul 18, 2022
- Q1 2022 EyePoint Pharmaceuticals Inc Earnings Call TranscriptMay 04, 2022€11.2 (-0.88%)Earnings
- EyePoint Pharmaceuticals Inc at B Riley Neuro & Ophthalmology Conference (Virtual) TranscriptApr 28, 2022
- Q4 2021 EyePoint Pharmaceuticals Inc Earnings Call TranscriptMar 03, 2022€8.75 (-3.31%)Earnings
- EyePoint Pharmaceuticals Inc Phase 1 DAVIO Trial Of EYP-1901 Results Conference Call TranscriptNov 13, 2021
- Q3 2021 EyePoint Pharmaceuticals Inc Earnings Call TranscriptNov 03, 2021€10.6 (+1.92%)Earnings
- EyePoint Pharmaceuticals Inc at Benzinga Healthcare Small Cap Conference (Virtual) TranscriptSep 30, 2021
- Q2 2021 EyePoint Pharmaceuticals Inc Earnings Call TranscriptAug 04, 2021€7.1 (+2.16%)Earnings
- Q1 2021 EyePoint Pharmaceuticals Inc Earnings Call TranscriptMay 05, 2021€8.7 (-1.14%)Earnings
- Q4 2020 EyePoint Pharmaceuticals Inc Earnings Call TranscriptMar 04, 2021€9.6 (-4.00%)Earnings
- EyePoint Pharmaceuticals Inc at Cowen Healthcare Conference (Virtual) TranscriptMar 03, 2021
- EyePoint Pharmaceuticals Inc to Host Key Opinion Leader Virtual Roundtable on the Future of Drug Delivery for Wet AMD TranscriptDec 04, 2020
- Q3 2020 EyePoint Pharmaceuticals Inc Earnings Call TranscriptNov 05, 2020€3.8 (+23.38%)Earnings
- Q2 2020 EyePoint Pharmaceuticals Inc Earnings Call TranscriptAug 05, 2020€6.06 (-0.98%)Earnings
- Q1 2020 EyePoint Pharmaceuticals Inc Earnings Call TranscriptMay 06, 2020€8.1 (-6.36%)Earnings
- Q4 2019 EyePoint Pharmaceuticals Inc Earnings Call TranscriptMar 05, 2020€13.1 (-25.14%)Earnings
- Q3 2019 EyePoint Pharmaceuticals Inc Earnings Call TranscriptNov 07, 2019€16 (-22.33%)Earnings
- Q2 2019 EyePoint Pharmaceuticals Inc Earnings Call TranscriptAug 07, 2019€11.03 (+1.75%)Earnings
- Q1 2019 EyePoint Pharmaceuticals Inc Earnings Call TranscriptMay 08, 2019€14.53 (-2.22%)Earnings
- EyePoint Pharmaceuticals Inc Six-Month Transition Period Ended December 31, 2018 Earnings Call TranscriptMar 14, 2019€22.5 (-1.75%)Earnings
EyePoint Pharmaceuticals Inc at Guggenheim Healthy Altitudes Summit Transcript
Good morning, everyone. My name is Yatin Suneja, and one of the biotech analyst here at Guggenheim. Thank you, everybody, for joining us this morning on day two of our Guggenheim Healthy Altitude Summit. Our first presenting company of today is EyePoint. And from the company, we have Chief Executive Officer, Nancy Lurker. We also have the Chief Financial Officer, George Elston.
Nancy, why don't you take maybe one to two minutes, give an intro to the story and then we'll go into the Q&A.
Yeah. So EyePoint Pharmaceuticals, we've got our lead asset. It's in a Phase 2 for wet AMD. It's a potential six-month bioerodible insert injected in the doctor's office intravitreally to be able to get patients at six months. So that, we're in two Phase 2 trials, wet AMD, diabetic retinopathy. Both trials are enrolling very, very nicely. And we expect to have readout on our Phase 2 data in December of this year.
That study will be 150 patients, and it is
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)